StockNews.com Begins Coverage on BIOLASE (NASDAQ:BIOL)

StockNews.com started coverage on shares of BIOLASE (NASDAQ:BIOL) in a research report issued to clients and investors on Monday. The brokerage set a “sell” rating on the medical technology company’s stock.

A number of other research firms have also issued reports on BIOL. Benchmark reaffirmed a “speculative buy” rating and issued a $0.40 target price on shares of BIOLASE in a research note on Wednesday, October 2nd. Ascendiant Capital Markets cut their price target on BIOLASE from $3.50 to $2.00 and set a “buy” rating for the company in a report on Tuesday, September 3rd.

BIOLASE Stock Performance

NASDAQ:BIOL opened at $0.01 on Monday. The company has a market capitalization of $367,477.00, a P/E ratio of 0.00 and a beta of 0.67. The firm has a 50-day moving average price of $0.01 and a two-hundred day moving average price of $0.04. BIOLASE has a twelve month low of $0.02 and a twelve month high of $1.94.

About BIOLASE

BIOLASE, Inc, together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, pediatric dentists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications.